These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 8074464)
21. [Inhibitory effect of p53 with deletion of c-terminal 356 - 393 amino acids on malignant phenotype of human lung cancer cell line]. Wang H; Li JZ; Lai BT; Yang XH; Zhang CY; Yue WT; Zhan XP Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):527-30. PubMed ID: 14690553 [TBL] [Abstract][Full Text] [Related]
22. Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cheng J; Yee JK; Yeargin J; Friedmann T; Haas M Cancer Res; 1992 Jan; 52(1):222-6. PubMed ID: 1727382 [TBL] [Abstract][Full Text] [Related]
23. Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes. Sharma S; Schwarte-Waldhoff I; Oberhuber H; Schäfer R Cell Growth Differ; 1993 Oct; 4(10):861-9. PubMed ID: 8274455 [TBL] [Abstract][Full Text] [Related]
24. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Wang Q; Beck WT Cancer Res; 1998 Dec; 58(24):5762-9. PubMed ID: 9865734 [TBL] [Abstract][Full Text] [Related]
25. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536 [TBL] [Abstract][Full Text] [Related]
26. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Fujiwara T; Grimm EA; Mukhopadhyay T; Cai DW; Owen-Schaub LB; Roth JA Cancer Res; 1993 Sep; 53(18):4129-33. PubMed ID: 8395976 [TBL] [Abstract][Full Text] [Related]
27. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. Runnebaum IB; Kreienberg R Hybridoma; 1995 Apr; 14(2):153-7. PubMed ID: 7590773 [TBL] [Abstract][Full Text] [Related]
28. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833 [TBL] [Abstract][Full Text] [Related]
29. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748 [TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Wesierska-Gadek J; Schmid G Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635 [TBL] [Abstract][Full Text] [Related]
31. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118 [TBL] [Abstract][Full Text] [Related]
32. Distinct promoter usage of mdm2 gene in human breast cancer. Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627 [TBL] [Abstract][Full Text] [Related]
33. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Lang D; Miknyoczki SJ; Huang L; Ruggeri BA Oncogene; 1998 Mar; 16(12):1593-602. PubMed ID: 9569027 [TBL] [Abstract][Full Text] [Related]
34. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. Liang Y; Wu J; Stancel GM; Hyder SM J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260 [TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Riccioni T; Cirielli C; Wang X; Passaniti A; Capogrossi MC Gene Ther; 1998 Jun; 5(6):747-54. PubMed ID: 9747454 [TBL] [Abstract][Full Text] [Related]
36. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774 [TBL] [Abstract][Full Text] [Related]
37. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Lin J; Jin X; Rothman K; Lin HJ; Tang H; Burke W Cancer Res; 2002 Jan; 62(2):376-80. PubMed ID: 11809683 [TBL] [Abstract][Full Text] [Related]
38. [The effect of adenovirus-mediated wild-type p53 expression on the growth of human pancreatic carcinoma cell line cells]. Guo H; Liu T; Gao J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):345-50. PubMed ID: 11717990 [TBL] [Abstract][Full Text] [Related]
39. The expression of p53 tumor suppressor gene in breast cancer cells is down-regulated by cytokine oncostatin M. Liu J; Li C; Ahlborn TE; Spence MJ; Meng L; Boxer LM Cell Growth Differ; 1999 Oct; 10(10):677-83. PubMed ID: 10547071 [TBL] [Abstract][Full Text] [Related]
40. Restoration of p53 function in anaplastic Wilms' tumor. Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]